Since our results demonstrate that NSMCE2 and MAL2 gene expression levels are reduced by pharmacological SE blockade, targeting SEs could work as a therapeutic approach to reduce these tumor promoting processes. The gene discussed is NSMCE2; the disease is neoplasm.